Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine for treating keratoconus

A keratoconus and pharmacological technology, applied in drug combinations, sensory diseases, pharmaceutical formulations, etc., can solve the problems of patients with great economic and physical and mental impact, cloudy implants, and missed treatment opportunities.

Active Publication Date: 2015-06-03
SHANDONG EYE INST
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] The etiology of keratoconus is still unknown, and it may be related to various reasons, such as mechanical friction of the ocular surface, long-term wearing of contact lenses, allergic inflammation of the ocular surface, etc. Early clinical intervention and treatment are still blank: even after early clinical diagnosis of keratoconus There is no method of treatment and intervention, only to wait for the natural development of the disease, wait for the cornea to expand to a certain stage, and rely on rigid contact lens correction to temporarily maintain vision. In the later severe stage, keratoplasty is the only way to restore part of the vision, but After keratoplasty, there may be immune rejection and chronic failure of corneal grafts, resulting in opacity of the grafts and the need for corneal transplantation again, and the increasing shortage of corneal materials undoubtedly prolongs the waiting time of patients and misses the best opportunity for treatment. The financial and physical impact on the patient is significant

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine for treating keratoconus
  • Medicine for treating keratoconus
  • Medicine for treating keratoconus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] Example 1: Effects of adding different concentrations of 5'aza on antioxidant genes in keratoconus stromal cells

[0019] Corneal tissue was treated overnight at 4°C with Dispase (50mg / ml) to remove the corneal epithelium and endothelium. After the corneal stroma was cut into pieces, it was digested with collagenase (1.25mg / ml) at 37°C for 6-8 hours, separated by pipetting, centrifuged, and the supernatant was discarded. , add DMEM / F-12 medium containing 10% fetal bovine serum at 37°C CO 2 Cultured in an incubator, 0.25% trypsin + 0.02% EDTA for passage. During the isolation and culture of corneal stromal cells, the P3 generation cells were taken 1X10 6 The nuclear protein was extracted according to the steps of the nuclear protein-cytoplasmic protein extraction kit (Thermo, 78833), and the expression of Nrf2 protein in the nucleus of normal and keratoconus stromal cells was detected by wetern blot. The expression level of nrf2 gene in the nucleus of keratoconus sampl...

Embodiment 2

[0022] Example 2: Effect of adding different concentrations of 5'aza on the expression of matrix degrading enzymes in keratoconus stromal cells

[0023] During the isolation and culture of keratoconus stromal cells, different concentrations of methylation inhibitor 5’aza (0, 0.5, 1 μm) were added, and after 48 hours of culture, 5×10 cells were taken. 5 , conventional western blot detection of the protein expression of matrix degrading enzyme UPA in keratoconus stromal cells. After 5'aza treatment, the expression of uPA protein in keratoconus stromal cells was lower than that of the untreated group, such as Figure 5 . In addition, collagen degradation experiments were used to add culture solutions containing plasminogen (100 mg / L) and different concentrations (0, 0.5, 1 μm) of 5'aza to the surface of the three-dimensional collagen gel of keratoconus stroma, cultured for 48 hours, and determined The hydroxyproline content in the solution is used as the collagen degradation ac...

Embodiment 3

[0024] Example 3: The effect of adding different concentrations of SFN on the expression of matrix-degrading enzymes in keratoconus stromal cells

[0025] During the isolation and culture of keratoconus stromal cells, different concentrations of SFN (0, 5, 10 μM) were added, and after 24 hours of culture, 1X10 6 The nuclear protein was extracted according to the procedure of the nuclear protein-cytoplasmic protein extraction kit (Thermo, 78833), and the expression level of Nrf2 protein in the nucleus of keratoconus stromal cells after drug treatment was detected by wetern blot. In addition, take the above cells 5X10 5 , conventional western blot detection of the protein expression of matrix degrading enzyme UPA in keratoconus stromal cells. After SFN treatment, the expression of Nrf2 protein in the nucleus of keratoconus stromal cells increased; and after drug treatment, the expression of UPA protein in keratoconus stromal cells was lower than that in the untreated group. In...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention aims at providing a medicine for treating keratoconus, which takes an Nrf2-ARE signal path as a target. The medicine can activate the signal path or improve the expression of downstream antioxidant genes NQO-1 and SOD2, so as to reduce the expression of matrix degrading enzymes; therefore, the medicine is suitable for the treatment of keratoconus. The medicine disclosed by the invention, which is used for treating the keratoconus by virtue of a methylation inhibitor 5-aza, can improve the expression of antioxidant genes of keratoconus matrix cells and can reduce the content of the matrix degrading enzymes as well.

Description

technical field [0001] The invention belongs to the technical field of ophthalmic disease treatment, and in particular relates to the application of a drug targeting the Nrf2-ARE signaling pathway in the treatment of keratoconus. Background technique [0002] Keratoconus (KC) is a corneal lesion characterized by dilatation of the cornea, causing the central part of the cornea to protrude forward, thinning into a conical shape, and producing highly irregular astigmatism. Histopathologically, corneal epithelial cell layer thinning, tearing of Bowman's membrane and Descemet's layer, corneal stroma thinning, decreased collagen content and scarring. The disease usually begins in adolescence, and patients can often use frame lenses to correct their vision in the early stage; as the disease progresses, they can wear rigid contact lenses or perform corneal surface lens surgery; in the late stage, the vision declines significantly, and corneal transplantation is required to restore p...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K45/00A61K31/12A61K31/26A61P27/02
Inventor 曲明俐周庆军边江王瑶杨玲玲
Owner SHANDONG EYE INST
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com